Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 66 entries
View as:

Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients with Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT04818671 Org: User:
Start: 04/26/21 End: 12/31/24 Due: 12/31/25

A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT02055066 Org: User:
Start: 01/31/14 End: 03/31/17 Due: 03/31/18

A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT05817435 Org: User:
Start: 03/13/23 End: 05/12/23 Due: 05/12/24

A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03334084 Org: User:
Start: 10/11/17 End: 09/19/18 Due: 09/19/19

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT05988073 Org: User:
Start: 11/29/23 End: 12/31/26 Due: 12/31/27

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants with DOK7-Congenital Myasthenic Syndromes (CMS)

Phase: N/A Priority: Normal
NCT ID: NCT06436742 Org: User:
Start: 09/24/24 End: 11/25/25 Due: 11/25/26

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

Phase: N/A Priority: Normal
NCT ID: NCT05907096 Org: User:
Start: 02/17/24 End: 07/31/26 Due: 07/31/27

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

Phase: N/A Priority: Normal
NCT ID: NCT05523167 Org: User:
Start: 10/12/22 End: 02/01/27 Due: 02/01/28

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT06203457 Org: User:
Start: 08/15/23 End: 02/03/25 Due: 02/03/26

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT06544499 Org: User:
Start: 10/18/24 End: 06/30/28 Due: 06/30/29

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)

Phase: N/A Priority: Normal
NCT ID: NCT04274452 Org: User:
Start: 06/29/20 End: 09/01/21 Due: 09/01/22

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT06742190 Org: User:
Start: 12/18/24 End: 12/31/29 Due: 12/31/30

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

Phase: N/A Priority: Normal
NCT ID: NCT04225156 Org: User:
Start: 06/02/20 End: 11/14/26 Due: 11/14/27

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Phase: N/A Priority: Normal
NCT ID: NCT06284954 Org: User:
Start: 08/20/24 End: 01/20/28 Due: 01/20/29

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT06655155 Org: User:
Start: 11/11/24 End: 06/14/27 Due: 06/14/28

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT04812925 Org: User:
Start: 11/17/21 End: 10/01/26 Due: 10/01/27

A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

Phase: N/A Priority: Normal
NCT ID: NCT06078553 Org: User:
Start: 02/13/24 End: 06/30/27 Due: 06/30/28

SAD and MAD Study With IV and SC Doses of ARGX-117

Phase: N/A Priority: Normal
NCT ID: NCT04532125 Org: User:
Start: 08/03/20 End: 08/26/22 Due: 08/26/23

A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04564066 Org: User:
Start: 08/18/20 End: 02/11/21 Due: 02/11/22

Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV

Phase: N/A Priority: Normal
NCT ID: NCT05163834 Org: User:
Start: 11/17/21 End: 03/08/22 Due: 03/08/23

Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04073589 Org: User:
Start: 07/17/19 End: 09/26/19 Due: 09/26/20

A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.

Phase: N/A Priority: Normal
NCT ID: NCT03770403 Org: User:
Start: 03/01/19 End: 06/30/22 Due: 06/30/23

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT04735432 Org: User:
Start: 02/05/21 End: 12/13/21 Due: 12/13/22

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

Phase: N/A Priority: Normal
NCT ID: NCT04280718 Org: User:
Start: 09/18/20 End: 03/01/27 Due: 03/01/28

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

Phase: N/A Priority: Normal
NCT ID: NCT06298565 Org: User:
Start: 11/04/24 End: 06/30/34 Due: 06/30/35